Grogan Jane's most recent trade in Biogen Inc was a trade of 8,450 Restricted Stock Unit done . Disclosure was reported to the exchange on Feb. 13, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Biogen | Jane Grogan | Head of Research | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2026 | 8,450 | 8,450 | - | - | Restricted Stock Unit | |
| Biogen | Jane Grogan | Head of Research | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Feb 2026 | 1,873 | 3,747 | - | - | Restricted Stock Unit | |
| Biogen | Jane Grogan | Head of Research | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Feb 2026 | 1,873 | 4,642 (0%) | 0% | 0 | Common Stock | |
| Biogen | Jane Grogan | Head of Research | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Feb 2026 | 1,385 | 3,176 (0%) | 0% | 0 | Common Stock | |
| Biogen | Jane Grogan | Head of Research | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Feb 2026 | 1,385 | 1,385 | - | - | Restricted Stock Unit | |
| Biogen | Jane Grogan | Head of Research | Payment of exercise price or tax liability using portion of securities received from the company at price $ 201.18 per share. | 06 Feb 2026 | 584 | 4,058 (0%) | 0% | 201.2 | 117,489 | Common Stock |
| Biogen | Jane Grogan | Head of Research | Payment of exercise price or tax liability using portion of securities received from the company at price $ 201.18 per share. | 06 Feb 2026 | 407 | 2,769 (0%) | 0% | 201.2 | 81,880 | Common Stock |
| Biogen | Jane Grogan | Head of Research | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Oct 2025 | 695 | 2,128 (0%) | 0% | 0 | Common Stock | |
| Biogen | Jane Grogan | Head of Research | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Oct 2025 | 695 | 695 | - | - | Restricted Stock Unit | |
| Biogen | Jane Grogan | Head of Research | Payment of exercise price or tax liability using portion of securities received from the company at price $ 154.27 per share. | 31 Oct 2025 | 337 | 1,791 (0%) | 0% | 154.3 | 51,989 | Common Stock |
| Biogen | Jane Grogan | Head of Research | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Feb 2025 | 5,620 | 5,620 | - | - | Restricted Stock Unit | |
| Biogen | Jane Grogan | Head of Research | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Feb 2025 | 1,385 | 1,876 (0%) | 0% | 0 | Common Stock | |
| Biogen | Jane Grogan | Head of Research | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Feb 2025 | 1,385 | 2,770 | - | - | Restricted Stock Unit | |
| Biogen | Jane Grogan | Head of Research | Payment of exercise price or tax liability using portion of securities received from the company at price $ 141.35 per share. | 06 Feb 2025 | 443 | 1,433 (0%) | 0% | 141.3 | 62,618 | Common Stock |
| Biogen | Jane Grogan | Head of Research | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Nov 2024 | 695 | 1,390 | - | - | Restricted Stock Unit | |
| Biogen | Jane Grogan | Head of Research | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Nov 2024 | 695 | 695 (0%) | 0% | 0 | Common Stock | |
| Biogen | Jane Grogan | Head of Research | Payment of exercise price or tax liability using portion of securities received from the company at price $ 173.79 per share. | 01 Nov 2024 | 204 | 491 (0%) | 0% | 173.8 | 35,453 | Common Stock |
| Biogen | Grogan Jane | Head of Research | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Feb 2024 | 4,155 | 4,155 | - | - | Restricted Stock Unit |